| Biomarker ID | 1045 |
| PMID | 23342084 |
| Year | 2013 |
| Biomarker | Early Growth Response 1 (Egr1) |
| Biomarker Basis | Expression Based |
| Biomolecule | mRNA |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Downregulated in Relapse (0.784 fold) |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways include: Differentiation pathway in PC12 cells, Regular glucocorticoid receptor pathway, PI3K/PLC/TRK pathway, Signaling events mediated by hepatocyte growth factor receptor (c-Met), RANKL regulation of apoptosis and immune response |
| Experiment | Relpase Vs No Relapse |
| Type of Biomarker | Prognostic |
| Cohort | Relapsed samples (n=38) and non relapsed samples (n=63) were chosen for the study. |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p = 0.017 |
| Method Used | qRT-PCR |
| Clinical | No |
| Remarks | The outcome parameter ‘‘relapse’’ refers to biochemical relapse, the rise in PSA levels over 0.2 ng/ml following a prior post-op PSA that was below threshold for the test. Non-relapse means that no biochemical relapse was observed in the patient during the clinical follow-up time frame. |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on independent patient dataset |
| Technical Name | NA |